CILOSTAZOL FOR TREATMENT OF PATIENTS WITH DIABETIC LEG ULCERS
Aim. The research was conducted for the purpose of improving treatment outcomes, reducing time on treatment, declining in disability, improving life quality of patient with diabetic ulcers.
Methods. In this research two groups of patients with diabetic leg ulcers were used: I group (51 patients) – treated with a standard procedure (control group) and second group (52 patients) – whether treatment was supplemented cytostazol (100 mg twice a day). For the evaluation the life quality of patients a questionnaire «SF - 36 Health Status Survey» was used during the treatment, the rate of the wound healing was calculated by the formula and 120 histological preparations were analyzed (20 patients of each group).
Results. After analysing the questionnaire results, significant differences were observed between groups of patients, manifested by de-emphasized role of physical problems, improved viability and psycho-emotional state with less manifestation of the differences in the control group. The reliable increase in the rate of wound healing was found in patients who took cilostazol. It was observed appearance of carbohydrate determinants in the endothelium of newly formed blood vessels after two weeks of treatment while in the most of the patients’ drugs of the control group there were no such obvious manifestations of regeneration.
Discussion. Regarding the results of the research, cilostazol is worth to be examined as perspective means for treatment of patients with diabetic ulcers. In turn, the results of lectinohistochemicals researches can be one of the objective tests of violation of balance of restorative-reparatory and destructively-necrotizing processes for patients with leg ulcers.
Naves, C. C. L. M. (2016). The Diabetic Foot: A Historical Overview and Gaps in Current Treatment. Advances in Wound Care, 5 (5), 191–197. doi: 10.1089/wound.2013.0518
Chammas, N. K., Hill, R. L. R., Edmonds, M. E. (2016). Increased Mortality in Diabetic Foot Ulcer Patients: The Significance of Ulcer Type. Journal of Diabetes Research, 2016, 1–7. doi: 10.1155/2016/2879809
Game, F. L., Apelqvist, J., Attinger, C., Hartemann, A., Hinchliffe, R. J. et. al. (2016). Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: a systematic review. Diabetes/Metabolism Research and Reviews, 32 (1), 154–168. doi: 10.1002/dmrr.2707
Bedenis, R., Stewart, M., Cleanthis, M., Robless, P., Mikhailidis, D. P., Stansby, G. (2014). Cilostazol for intermittent claudication. Cochrane Database of Systematic Reviews. doi: 10.1002/14651858.cd003748.pub4
Kobza, I. I., Terletskiy, I. R., Verhola, M. R., Savchenko, A. A., Vykhtyuk, T. I. (2016). Likuvannia patsiientiv z khronichnymy vyrazkamy nyzhnikh kintsivok [Treatment of patients with trophic ulcers of the lower extremities]. Klinichna flebolohiia [Clinical phlebology], 9 (1), 43–47.
Kobza, I. I., Terletskiy, I. R., Verhola, M. R., Savchenko, A. A., Vykhtyuk, T. I. (2016). Rezultaty likuvannia patsiientiv z trofichnymy vyrazkamy nih [Results of treatment of patients with trophic ulcers of the leg]. Halytskyi likarskyi visnyk [Galician Medical Journal], 23 (3), 11–14.
De Franciscis, S., Gallelli, L., Battaglia, L., Molinari, V., Montemurro, R., Stillitano, D. M. et. al. (2015). Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease. International Wound Journal, 12 (3), 250–253. doi: 10.1111/iwj.12085
Wada, T., Onogi, Y., Kimura, Y., Nakano, T., Fusanobori, H., Ishii, Y. et. al. (2013). Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions. European Journal of Pharmacology, 707 (1-3), 120–129. doi: 10.1016/j.ejphar.2013.03.016
Spear, M. (2013). Acute or Chronic? Whatʼs the Difference? Plastic Surgical Nursing, 33 (2), 98–100. doi: 10.1097/psn.0b013e3182965e94
Svyrydov, M. V. (2008). Innovatsiini pidkhody do zahoiennia obshyrnykh ranovykh defektiv stop u khirurhii piznikh uskladnen u khvorykh iz syndromom diabetychnoi stopy [Innovative approaches to the healing of extensive wound defect of feet in the surgery of late complications in patients with diabetic foot syndrome]. Klinichna endokrynolohiia ta endokrynna khirurhiia [Clinical endocrinology and endocrine surgery], 4 (25), 10–14.
Ware, J. E. (2000). SF-36 Health Survey Update. Spine, 25 (24), 3130–3139. doi: 10.1097/00007632-200012150-00008
Preima, Kh. I., Yashchenko, A. M. (2009). Rol hlikokoniuhativ u protsesakh morfohenezu shkiry potomstva na tli hipotyreozu materynskoho orhanizmu [Role of glycoconjugates in the processes of skin morphogenesis in the offspring with underlying maternal organism’s hypothyrosis]. Bukovynskyi medychnyi visnyk [Bukovinian Medical Herald Journal], 13 (4), 232–236.
Yashchenko, A. M., Pankevych, L. V., Lutsyk, A. D. (2012). Rat liver carbohydrate alterations in streptozotocin-induced diabetic rats. European Journal of Anatomy, 16 (2), 82–90.
Copyright (c) 2017 Ihor Kobza, Ivan Terletskyi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.